FUNDACION PARA LA INVESTIGACION MEDICA APLICADA 09 Dec | FUNDACION PARA LA INVESTIGACION MEDICA APLICADA | Pamplona
Position OverviewThe Oncogenes and Effector Target (OnTarget) group is looking for a postdoctoral scientist to lead a project aimed at the characterization of a new combination strategy based on KRAS inhibitors for the treatment of pancreatic cancer.
ResponsibilitiesTesting of novel combinatorial therapies using in vitro (cell viability, cell cycle, apoptosis, time-to-progression assays) and in vivo (human cell- and patient-derived xenografts, mouse allografts) models.Dissection of the mechanism of action of drug combinations or nominated genes using high-throughput (RNAseq, scRNAseq, ChIPseq, WES, multiplex cytometry and IF, proteomics and/or metabolomics) and focused (Western blot, qPCR) approaches.Project GoalsOur work aims to understand the underlying mechanisms involved in mutant KRAS-driven oncogenesis around two unresolved aspects of KRAS biology:
The identification of key transcriptional and functional mediators of cancer initiation and progression.The discovery of novel therapeutic approaches and the characterization of resistance mechanisms.Collaboration OpportunitiesThe project is in line with previous studies by the group and will be carried out within the framework of the new Comprehensive Cancer Center of the University of Navarra (CCUN).
The project will provide opportunities for interaction with other groups (internally, nationally, and internationally) as well as industry partners.
Contract DetailsThis is a three-year contract funded by Worldwide Cancer Research, extendable for an additional year pending on additional funding obtained by the candidate.
#J-18808-Ljbffr